ALLK_OUT_1 [2025-04-02 09:38:58 -0400] 2822 Bytes | 754 tokens | Cum: 754 tkns (9.43% of 8k)
==========================================================================

Alright, let’s light it up, because it's 9:38:57 AM on Wed Apr 02, 2025 -0400, and I'm charging into Allakos (ALLK), popping from 0.217 to 0.3155. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Allakos (ALLK)
IPO: 2018-07-19 (6 Years Ago)
Market Cap: $19,574,104
Shares Outstanding: 90,200,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Here's the first list of news for Allakos:

C1 - Today 08:00AM - Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
C2 - Mar-12-25 04:02PM - Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
C3 - Jan-29-25 05:39AM - BioAge drops obesity drug; Akero, 89bio cash in on MASH data
C4 - Jan-28-25 01:37PM - Allakos cuts 75% of workforce after chronic hives trial failure
C5 - Jan-27-25 07:00AM - Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
C6 - Nov-11-24 12:00PM - All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
C7 - Nov-06-24 04:02PM - Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
C8 - Oct-10-24 04:02PM - Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Allakos (ALLK)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ALLK_OUT_3 [2025-04-02 09:39:01 -0400] 1116 Bytes | 346 tokens | Cum: 1102 tkns (13.78% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share**
Date: Today 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054176/0/en/Allakos-Inc-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-LLC-for-0-33-in-Cash-per-Share.html

April 02, 2025 08:00 ET| Source:Allakos Inc.Allakos Inc.

SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0.33 in cash per share of Allakos common stock (“Allakos Common Stock”).

Allakos’ Board of Directors

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALLK_OUT_5 [2025-04-02 09:39:02 -0400] 886 Bytes | 278 tokens | Cum: 1441 tkns (18.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T12:34:56Z - Concentra Biosciences To Acquire Allakos - Quick Facts...
A2 - 2025-04-02T12:13:31Z - Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash pe...
A3 - 2025-04-02T12:00:00Z - Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash pe...
A4 - 2025-04-02T12:06:08Z - Allakos agrees to Concentra Biosciences acquisition By Investing.com...
A5 - 2025-03-12T21:01:09Z - Allakos GAAP EPS of $0.00...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALLK_OUT_7 [2025-04-02 09:39:07 -0400] 1098 Bytes | 298 tokens | Cum: 1741 tkns (21.76% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Concentra Biosciences To Acquire Allakos - Quick Facts**Date: 2025-04-02Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3526263/concentra-biosciences-to-acquire-allakos-quick-facts.aspxAllakos Inc. (ALLK) has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire Allakos for $0.33 in cash per share of Allakos common stock. A wholly owned subsidiary of Concentra will commence a tender offer by April

15, 2025 to acquire all outstanding shares of Allakos common stock. The merger transaction is expected to close in May 2025.

Closing of the offer is subject to certain conditions, including the tender of Allakos common stock representing at least a majority of the total number of outstanding shares, the availability of at least $35.5 million of cash at closing, and other customary closing conditions.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALLK_OUT_9 [2025-04-02 09:39:08 -0400] 1075 Bytes | 335 tokens | Cum: 2186 tkns (27.32% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-02T12:00:00Z - Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
B2 - 2025-02-10T22:36:00Z - Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
B3 - 2025-01-31T19:20:27Z - Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
B4 - 2024-11-04T18:00:00Z - Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
B5 - 2024-08-07T20:02:00Z - Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
B6 - 2024-06-25T20:02:00Z - Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALLK_OUT_11 [2025-04-02 09:39:12 -0400] 745 Bytes | 234 tokens | Cum: 2422 tkns (30.28% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/02/3054176/0/en/Allakos-Inc-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-LLC-for-0-33-in-Cash-per-Share.htmlAllakos Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire Allakos for $0.33 in cash per share. The transaction is expected to close in May 2025.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALLK_OUT_13 [2025-04-02 09:39:14 -0400] 1094 Bytes | 294 tokens | Cum: 2803 tkns (35.04% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-02 8-K Item1.01 Entry into a Material Definitive Agrmt.

Agrmt and Plan of Merger

On April 1, 2025, Allakos Inc. (the Company) entered into an Agrmt and Plan of Merger (the Merger Agrmt) with Concentra Biosciences, LLC, a Delaware limited liability company (Concentra)...

S2 - 2025-03-12 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the other financial information a...

S3 - 2025-03-12 8-K Item 2.02 Results of Oper and Fin Cond.

On March 12, 2025, Allakos Inc. (the Company) issued a press release reporting its financial results for the fourth quarter ended December 31, 2024. The full text of the press release is attached as Exhibit 99.1 to this C...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALLK_OUT_15 [2025-04-02 09:39:15 -0400] 1098 Bytes | 291 tokens | Cum: 3096 tkns (38.70% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item1.01 Entry into a Material Definitive Agreement.

Agreement and Plan of Merger

On April 1, 2025, Allakos Inc. (the Company) entered into an Agreement and Plan of Merger (the Merger Agreement) with Concentra Biosciences, LLC, a Delaware limited liability company (Concentra), and Concentra Merger Sub III, Inc., a Delaware corporation and a wholly owned subsidiary of Concentra (Merger Sub). The Merger Agreement provides for, among other things: (i) the acquisition of all of the Companys outstanding shares of common stock, par value $0.001 per share (the Common Stock) by Concentra through a cash tender offer (the Offer) by Merger Sub, for a price per share of the Common Stock of $0.33 in cash (the Offer Price) and (ii) the merger of Merger Sub with and into the Company (the Merger) with the Company surviving the Merger.

A transaction committee consisting solely of disinterested

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALLK_OUT_17 [2025-04-02 09:39:19 -0400] 1098 Bytes | 261 tokens | Cum: 3359 tkns (41.99% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): and independent members of the Companys Board of Directors (the Board), and all members of the Board, have unanimously: (i) determined that the Offer, the Merger and the other transactions contemplated by the Merger Agreement (collectively, the Transactions) are fair to, and in the best interest of, the Company and its stockholders; (ii) approved and declared advisable the Merger and the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the Transactions; (iii) resolved that the Merger Agreement and the Merger shall be governed by and effected under Section 251(h) of the Delaware General Corporation Law (the DGCL) and that the Merger shall be consummated as soon as practicable following the Offer Closing Time (as defined in the Merger Agreement); and (iv) recommended that the Companys stockholders accept the Offer and tender their shares of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALLK_OUT_19 [2025-04-02 09:39:30 -0400] 4569 Bytes | 1333 tokens | Cum: 4779 tkns (59.74% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-----------------------+
| Volume: 0 | Perf Month: -19.63% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 2.40M | Perf Quarter: -83.31% | Short Float: 2.20% | ROE: -93.54% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 0.70 | ROI: -146.95% |
+-------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 28.24 | Market Cap: 19.57M | Short Interest: 1.67M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.02 | Shs Outstand: 89.65M | Beta: 0.22 | EPS Surprise: 100.00% |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -11.98% | Shs Float: 75.74M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -34.21% | Inst Own: 78.56% | Sales past 5Y: 0.00% | Earnings: Mar 12 AMC |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -71.67% | Insider Own: 16.03% | Employees: 61 | |
+-------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -9.66% | Insider Trans: 0.00% | Debt/Eq: 0.05 | |
+-------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Allakos Inc. (ALLK) by Radford Harlan Baird (Chief Financial Officer) on 2025-03-05
- Common Stock: 14161 shares at $0.26 (D)

Inside Trans: Allakos Inc. (ALLK) by Alexander Robert (Chief Executive Officer) on 2025-03-06
- Common Stock: 31370 shares at $0.26 (D)

Inside Trans: Allakos Inc. (ALLK) by Tomasi Adam (President) on 2025-03-05
- Common Stock: 20017 shares at $0.26 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -115818000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.317
Average Volume: 971153.87
30-Day High: 0.317
30-Day Low: 0.217

[Detailed Financials: TTM 2024]
- Total Assets: $96,601,000.0
- Total Liabilities: $17,784,000.0
- Total Equity: $78,817,000.0
- Current Assets: $85,586,000.0
- Current Liabilities: $17,784,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.3

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-48,687,000.0

[Detailed Financials: FY 2024]
- Total Assets: $96,601,000.0
- Total Liabilities: $17,784,000.0
- Total Equity: $78,817,000.0
- Current Assets: $85,586,000.0
- Current Liabilities: $17,784,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.3

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-48,687,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ALLK_OUT_21 [2025-04-02 09:39:33 -0400] 676 Bytes | 167 tokens | Cum: 5191 tkns (64.89% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ALLK_IN_23 [2025-04-02 09:39:34 -0400] 126 Bytes | 29 tokens | Cum: 5284 tkns (66.05% of 8k)
==========================================================================

====================================
[2025-04-02 09:39:34] # Analysis Completed
Elapsed Time: 37.01 seconds